Kamada (KMDA) Flat As Market Gains: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.79, making no change from the previous trading session. This change lagged the S&P 500’s daily gain of 0.36%. Meanwhile, the Dow gained 0.36%, and the Nasdaq, a tech-heavy index, added 0.34%.

Heading into today, shares of the biopharmaceutical had lost 6.01% over the past month, lagging the Medical sector’s loss of 0.3% and the S&P 500’s gain of 0.64% in that time.

Investors will be hoping for strength from KMDA as it approaches its next earnings release. The company is expected to report EPS of $0.05, up 66.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $22.87 million, up 31.14% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $0.47 per share and revenue of $126.91 million, which would represent changes of -17.54% and +10.87%, respectively, from the prior year.

Any recent changes to analyst estimates for KMDA should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. KMDA is holding a Zacks Rank of #1 (Strong Buy) right now.

Looking at its valuation, KMDA is holding a Forward P/E ratio of 12.41. This represents a discount compared to its industry’s average Forward P/E of 20.76.

The Medical – Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 33% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow KMDA in the coming trading sessions, be sure to utilize Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Kamada Ltd. (KMDA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
Source: Zacks



Leave a Reply